Clinical trials: Significant Prostate Cancer
Prostate Cancer
PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy
The principal aim of this study is to determine if PET/MRI imaging with 18-F fluciclovine (Axumin) identifies those men with false negative MRI fusion targeted biopsy (MRFTB) of PI-RADS 4 and 5 lesions.
- Trial name
- NCT03635866
- Testing
- Fluciclovine PET/MRI
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Prostate Cancer (Diagnosis), Prostate Cancer
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures.
- Trial name
- INSIGHT-PCa (NCT07398690)
- Testing
- Diagnostic Procedure
- Where
- South Korea
- Volunteers
- 1,432 people
- Sponsor
- In Gab Jeong, MD
Prostate Cancer
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
This trial aims to develop and validate the urinary multimarker sensor which can measure trace amounts of biomarkers from naturally voided urine in men referred with clinical suspicion of prostate cancer who have had no prior…
- Trial name
- NCT04825002
- Testing
- Urinary multimarker sensor
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Asan Medical Center
Prostate Cancer, Magnetic Resonance Imaging
Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa).
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy
- Trial name
- NCT03044197
- Testing
- MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Prostate Cancer, Active Surveillance for Prostate Cancer
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease.
- Conditions
- Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques
- Trial name
- MUS-AS (NCT07386171)
- Testing
- Micro-Ultrasound (mUS)
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prostate Cancer (Diagnosis)
Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging
The goal of this clinical trial is to prospectively investigate the evolution of lesions in biparametric magnetic resonance imaging (bpMRI) of the prostate in men with no clinically significant prostate cancer (csPCa) in their…
- Trial name
- REMRI (NCT07369570)
- Testing
- MRI
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- University of Eastern Finland
Prostate Cancer
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.
- Trial name
- NCT03081481
- Testing
- PRX302
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Sophiris Bio Corp
Prostate Cancer Diagnosis
PSMA PET Scan and mpMRI for Prostate Cancer Detection
Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.
- Trial name
- NCT05820724
- Testing
- PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University
Prostate Cancer
TULIP ReTrain Study
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two…
- Trial name
- TULIP ReTrain (NCT06974539)
- Testing
- Multiparametric ultrasound with contrast (Sonovue and Optison)
- Where
- Netherlands
- Volunteers
- 212 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostate Carcinoma
Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
This clinical trial studies whether transperineal micro-ultrasound can be used to detect prostate cancer during biopsy. Transrectal ultrasound is often used during prostate biopsy.
- Trial name
- NCT07075705
- Testing
- Biopsy of Prostate, Magnetic Resonance Imaging, Micro-ultrasound Imaging
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
The percentage of malignant prostate tumors detected very early is constantly increasing and the number of well differentiated tumors, with small volume and low risk of progression increases.
- Trial name
- HIFUSA (NCT03531099)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
Prostate Cancer (Adenocarcinoma)
Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions
The goal of this observational study is to assess the chance to predict prostate cancer with the analysis of specific values found in images obtained from RMmp (multiparametric magnetic resonance imaging) of patients who went…
- Trial name
- NCT06774781
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer, Prostate Neoplasm
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
With the general acceptance of MRI and technical advances in biopsy technique of the prostate, new questions arise concerning the selection of patients, the approach, the appropriate technique, the lesions to target and the…
- Trial name
- PROSOVI (NCT03819751)
- Testing
- MRI-targeted prostate biopsy
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer, PSA
MRI Prostate for Chinese Men Being Screened for Prostate Cancer
Under the prostate cancer screening protocol of the project 'Prevention of Obesity-related Cancers', men with elevated PSA with higher prostate cancer risk (PSA 4-10 ng/mL with high Prostate Health Index (PHI) ≥35, or PSA>10…
- Conditions
- Prostate Cancer, PSA, MRI
- Trial name
- NCT03891732
- Testing
- MRI prostate
- Where
- 2 sites in Hong Kong
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy
Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.
BIOPSTAGE is a prospective, non-randomized, diagnostic, multi-cohort investigational study to evaluate the impact of pelvic Multi-parametric 3-Tesla magnetic resonance imaging (mp-3TMRI) and whole-body 68Ga-PSMA PET/CT for…
- Conditions
- 68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy, Prostate Cancer, TNM Staging
- Trial name
- BIOPSTAGE (NCT03465579)
- Testing
- pelvic MRI, 68Ga-PSMA PET/CT
- Where
- 2 sites in Italy
- Volunteers
- 261 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
Biparametric MRI for Detection of Significant Prostate Cancer
Our aim is to develop a new diagnostic approach to improve the diagnosis of men suspicious of having significant prostate cancer (sPCa).
- Trial name
- BIDOC (NCT02584179)
- Testing
- Biparametric MRI before biopsy
- Where
- Denmark
- Volunteers
- 1,063 people
- Sponsor
- Herlev Hospital
Prostate Cancer, Multiple Myeloma
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering…
- Conditions
- Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT04731844
- Testing
- Curcumin plus Piperine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Prostate Cancer
Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging
This randomized prospective multi center study is designed to confirm a new diagnostic pathway in primary diagnosis of clinically significant prostate cancer by combination of serum levels of prostate specific antigen (PSA)…
- Trial name
- PRIMA (NCT04993508)
- Testing
- PSA test, multiparametric prostate Magnetic Resonance Imaging (mpMRI), targeted MRI/US fusion-guided biopsy
- Volunteers
- 1,908 people
- Sponsor
- Heinrich-Heine University, Duesseldorf